DavidEMoodyMD

PubMed

• 2 citations
  Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus).
  Niora J Fabian, David E. Moody, Olga Averin, Wenfang B. Fang, Morgan Jamiel, James G. Fox, Monika Burns, Jennifer L Haupt> ;Journal of the American Association for Laboratory Animal Science. 2021 Jul 19
• 4 citations
  Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus).
  Casey Fitz, Anna Goodroe, David E. Moody, Wenfang B. Fang, Saverio Capuano> ;Journal of the American Association for Laboratory Animal Science. 2021 Mar 1
• Analysis for Alpha-Pyrrolidinovalerophenone and Its 2-Oxo-PVP Metabolite in Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
  David M. Andrenyak, David E. Moody, Jonathan M Crites, Michael H. Baumann> ;Journal of Analytical Toxicology. 2021 Feb 6
• 4 citations
  Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?
  Tao Liu, Tamorah R Lewis Md PhD, Jason N. Moore, Walter K. Kraft, Estelle B. Gauda, David Alan Sartori, David E. Moody, Jogarao V. S. Gobburu, Vijay Ivaturi> ;CPT. 2019 Jul 1
• 1 citations
  The inhibition of first-pass metabolism of ethanol by H2-receptor antagonists: a tabulated review.
  David E. Moody> ;Expert Opinion on Drug Safety. 2018 Oct 1
• 5 citations
  Inhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants.
  David E. Moody, Yueqiao Fu, Wenfang B. Fang> ;Basic & Clinical Pharmacology & Toxicology. 2018 Sep 1
• 8 citations
  Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
  Marisa S. Briones, Steven Shoptaw, Ryan Cook, Matthew J. Worley, Aimee-Noelle Swanson, David E. Moody, Wenfang B. Fang, John Tsuang, Benjamin A. Furst, Keith G. Heinze...> ;Drug and Alcohol Dependence. 2018 Aug 1
• 21 citations
  The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
  Jason N. Moore, Marc R. Gastonguay, Chee M. Ng, David E. Moody, Wenfang B. Fang, Michelle E. Ehrlich, Walter K. Kraft> ;Clinical Pharmacology and Therapeutics. 2018 Jun 1
• 27 citations
  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.
  David M. Andrenyak, David E. Moody, Matthew H. Slawson, Daniel S. O'Leary, Margaret Haney> ;Journal of Analytical Toxicology. 2017 May 1
• Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil
  Kenneth Grasing, Deepan Mathur, Cherilyn DeSouza, Thomas F. Newton, David E. Moody, Marc G. Sturgill> ;The American Journal on Addictions. 2016 Aug 1
• 28 citations
  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
  Chee M. Ng, Erin Dombrowsky, Hopi Lin, Michelle E. Erlich, David E. Moody, Jeffrey S. Barrett, Walter K. Kraft> ;Pharmacotherapy. 2015 Jul 1
• 17 citations
  Azole Antifungal Inhibition of Buprenorphine, Methadone and Oxycodone In Vitro Metabolism
  David E. Moody, Fenyun Liu, Wenfang B. Fang> ;Journal of Analytical Toxicology. 2015 Jun 1
• 19 citations
  A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Correc...
  John F. Carlquist, David E. Moody, Stacey Knight, Eric G. Johnson, Wenfang B. Fang, John A. Huntinghouse, Jeffrey Rollo, Lynn R. Webster, Jeffrey L. Anderson> ;Molecular Diagnosis & Therapy. 2015 Apr 23
• 6 citations
  The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection
  Jeanette M. Tetrault, Elinore F. McCance-Katz, David E. Moody, David A. Fiellin, Bonnie S. Lruie, An T. Dinh, Lynn E. Fiellin> ;Journal of Substance Abuse Treatment. 2015 Apr 1
• 12 citations
  Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals
  Carmen L. Masson, Petrie M. Rainey, David E. Moody, Elinore F. McCance-Katz> ;The American Journal on Addictions. 2014 Jan 1
• 8 citations
  In vitro Inhibition of Methadone and Oxycodone Cytochrome P450-Dependent Metabolism: Reversible Inhibition by H2-Receptor Agonists and Proton-Pump Inhibitors
  David E. Moody, Fenyun Liu, Wenfang B. Fang> ;Journal of Analytical Toxicology. 2013 Oct 1
• 21 citations
  Determination of Oxycodone, Noroxycodone and Oxymorphone by High-Performance Liquid Chromatography–Electrospray Ionization-Tandem Mass Spectrometry in Human Matrices: ...
  Wenfang B. Fang, Michelle R. Lofwall, Sharon L. Walsh, David E. Moody> ;Journal of Analytical Toxicology. 2013 Jul 1
• 18 citations
  Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine
  David E. Moody> ;Expert Opinion on Drug Metabolism & Toxicology. 2013 May 14
• 37 citations
  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
  R. Douglas Bruce, David E. Moody, Frederick L. Altice, Marc N. Gourevitch, Gerald Friedland> ;Expert Review of Clinical Pharmacology. 2013 May 1
• 5 citations
  Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
  R. Douglas Bruce, David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons, Gerald Friedland> ;The American Journal of Drug and Alcohol Abuse. 2013 Feb 19
• 43 citations
  Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis)
  Elizabeth A Nunamaker, Lisa Halliday, David E. Moody, Wenfang B. Fang, Matthew Lindeblad, Jeffrey D Fortman> ;Journal of the American Association for Laboratory Animal Science. 2013 Jan 1
• 16 citations
  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.
  Michelle R. Lofwall, David E. Moody, Wenfang B. Fang, Paul A. Nuzzo, Sharon L. Walsh> ;Journal of Clinical Pharmacology. 2012 Apr 1
• 26 citations
  Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
  Elinore F. McCance-Katz, David E. Moody, Sudha Prathikanti, Gerald Friedland, Petrie M. Rainey> ;Drug and Alcohol Dependence. 2011 Nov 1
• 55 citations
  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
  Lisa S. Middleton, Paul A. Nuzzo, Michelle R. Lofwall, David E. Moody, Sharon L. Walsh> ;Addiction. 2011 Aug 1
• 7 citations
  Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
  R. Douglas Bruce, David E. Moody, Wenfang B. Fang, Diane Chodkowski, Laurie Andrews, Gerald Friedland> ;The American Journal of Drug and Alcohol Abuse. 2011 Jul 13
• Join now to see all